shortage of tirzepatide The FDA says the Zepbound is over. That's rattling the weight loss industry Eli Lilly's Weight-Loss, Diabetes Drug

Mechanism 3: Gastrointestinal fluid losses Nausea, vomiting, and diarrhea are among the most commonly reported side effects of tirzepatide, particularly during dose escalation

doi: 10.1111/bjd.12886

doi: 10.1177/00220345950740111201 199 WagnerA.WangC.FesslerJ.DeTomasoD.Avila-PachecoJ.KaminskiJ.et al

Weeks 9-12: the three-month checkpoint Clinical trials consistently show that the 12-week mark provides the first reliable predictor of long-term success

The researchers then looked at whether women were diagnosed with a new breast cancer in two different cohorts: the full group of 111,646 women and a smaller cohort of 30,528 women, including one-to-one controls for each of the 15,264 GLP-1 cases, matched across age, race, ethnicity, BMI, breast density, and diabetes status to limit bias and potential confounding